Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy epigenomic profiling for cancer subtyping.
Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Baca SC, et al. Among authors: wen py. Nat Med. 2023 Nov;29(11):2737-2741. doi: 10.1038/s41591-023-02605-z. Epub 2023 Oct 21. Nat Med. 2023. PMID: 37865722 Free PMC article.
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML. Baca SC, et al. Among authors: wen py. Nat Med. 2024 Mar;30(3):907. doi: 10.1038/s41591-023-02735-4. Nat Med. 2024. PMID: 38049623 Free PMC article. No abstract available.
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Among authors: wen py. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R, Weisman HR, Gonzalez Castro LN, Druck N, Chanoch-Myers R, Lee JJY, Mylvaganam R, Lee Servis R, Fung JM, Lee CK, Nagashima H, Miller JJ, Arrillaga-Romany I, Louis DN, Wakimoto H, Pisano W, Wen PY, Mak TW, Sanson M, Touat M, Landau DA, Ligon KL, Cahill DP, Suvà ML, Tirosh I. Spitzer A, et al. Among authors: wen py. Cancer Cell. 2024 May 13;42(5):904-914.e9. doi: 10.1016/j.ccell.2024.03.008. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579724 Free article.
Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.
Wirsching HG, Felsberg J, Prummer M, Moisoiu V, Lourman R, Hertler C, Antonios M, Cimino PJ, Roth P, Gorlia T, Prins RM, Cloughesy T, Wen PY, Holland EC, Reifenberger G, Weller M. Wirsching HG, et al. Among authors: wen py. Acta Neuropathol. 2023 Oct;146(4):647-649. doi: 10.1007/s00401-023-02617-6. Epub 2023 Aug 13. Acta Neuropathol. 2023. PMID: 37573572 Free PMC article. No abstract available.
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
Ahluwalia MS, Ozair A, Drappatz J, Ye X, Peng S, Lee M, Rath S, Dhruv H, Hao Y, Berens ME, Walbert T, Holdhoff M, Lesser GJ, Cloughesy TF, Sloan AE, Takebe N, Couce M, Peereboom DM, Nabors B, Wen PY, Grossman SA, Rogers LR. Ahluwalia MS, et al. Among authors: wen py. Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-4098. Online ahead of print. Clin Cancer Res. 2024. PMID: 38836759
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.
Chen JJ, Vincent MY, Shepard D, Peereboom D, Mahalingam D, Battiste J, Patel MR, Juric D, Wen PY, Bullock A, Selfridge JE, Pant S, Liu J, Li W, Fyfe S, Wang S, Zota V, Mahoney J, Watnick RS, Cieslewicz M, Watnick J. Chen JJ, et al. Among authors: wen py. Commun Med (Lond). 2024 May 21;4(1):95. doi: 10.1038/s43856-024-00520-z. Commun Med (Lond). 2024. PMID: 38773224 Free PMC article.
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Rahman R, Shi DD, Reitman ZJ, Hamerlik P, de Groot JF, Haas-Kogan DA, D'Andrea AD, Sulman EP, Tanner K, Agar NYR, Sarkaria JN, Tinkle CL, Bindra RS, Mehta MP, Wen PY. Rahman R, et al. Among authors: wen py. Neuro Oncol. 2024 Mar 22:noae072. doi: 10.1093/neuonc/noae072. Online ahead of print. Neuro Oncol. 2024. PMID: 38770568
Glioma.
Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Weller M, et al. Among authors: wen py. Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y. Nat Rev Dis Primers. 2024. PMID: 38724526 Review.
639 results